ReviewBioconjugate chemistry2026
DNA Nanostructures for siRNA Delivery.
Review in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Small interfering RNAs (siRNAs) represent an emerging class of versatile nucleic acid drugs for a broad spectrum of genetic and metabolic disorders. Since siRNAs can be developed to silence any target gene with relative ease compared to conventional drugs, there is enormous potential in this therapeutic modality for combating a variety of illnesses. However, its application is limited by low biostability, rapid clearance, and poor biodistribution of naked RNA. This is overcome by employing backbone modifications, conjugation of cell-targeting ligands, and the use of nanocarriers. DNA-based nanostructures are well suited to carry siRNA drugs since the use of DNA as a construction material provides the ability to tune the size, shape, and other morphological features of the nanostructure. DNA nanostructures also allow easy loading of multiple siRNA drugs with stoichiometric precision, enable functionalization with various targeting and tracking agents, and can be designed to deliver siRNA cargo in response to various stimuli. In this review, we provide an overview of recent reports on the use of DNA-based nanostructures to achieve targeted delivery of siRNA in vitro and in vivo. We discuss aspects of nanostructure design for various drug-loading and drug-release strategies and pharmacodynamic and pharmacokinetic properties of DNA nanocarriers and provide a survey of various diseases that have been targeted by siRNA-carrying DNA nanostructures. We also highlight the challenges facing these new-generation nanocarriers in achieving their therapeutic potential and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.